pharmaceutical executive top 50 pharma companies report

Sponsored bywww.dsm.com


PHARMACEUTICAL EXECUTIVE40

Will the recent wave of megamergers and a slow revival of biotech fi nancing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning profi ts and placating a restive new breed of payers and the ever-expectant patient

By Jerry Cacciotti and Patrick Clinton

12TH ANNUAL PHARM EXEC 50

TheLullbetween

Lullbetween

Lulltwo

Lulltwo

LullSTORMS

40 PHARMACEUTICAL EXECUTIVE


MAY 2011 www.pharmexec.com 41

0%

2%

4%

6%

8%

10%

StadaApotexNycomedHospiraActavisShionogiDainippon SumitomoKyowa Hakko KirinLundbeckWatsonCephalonWarner ChilcottAlconShireBiogen IdecCelgeneOtsukaUCBCSLForestAllerganGenzymeMenariniMitsubishi TanabeChugaiServierMylanBaxter InternationalGilead SciencesMerck KGaAEisaiDaiichi SankyoAstellasNovo NordiskBoehringer IngelheimTakedaBayerAmgenTevaBristol-Myers SquibbAbbottEli LillyJohnson & JohnsonAstraZenecaGlaxoSmithKlineRocheMerckSano�-AventisNovartisP�zer

Stad

a

Apot

ex

Nyc

omed

Hos

pira

Acta

vis

Shio

nogi

Dai

nipp

on S

umito

mo

Kyow

a Hak

ko K

irin

Lund

beck

Wat

son

Ceph

alon

War

ner C

hilc

ott

Alco

n

Shire

Biog

en Id

ec

Celg

ene

Ots

uka

UCB

CSL

Fore

st

Alle

rgan

Gen

zym

e

Men

arin

i

Mits

ubis

hi T

anab

e

Chug

ai

Serv

ier

Mylan

Baxt

er In

tern

atio

nal

Gile

ad S

cien

ces

Mer

ck K

GaA

Eisa

i

Dai

ichi

San

kyo

Aste

llas

Nov

o Nor

disk

Boeh

ringe

r Ing

elhe

im

Take

da

Baye

r

Amge

n

Teva

Bris

tol-M

yers

Squ

ibb

Abbo

tt

Eli L

illy

John

son

& J

ohns

on

AstraZ

enec

a

Gla

xoSm

ithKl

ine

Roch

e

Mer

ck

Sano

�-Av

entis

Nov

artis

P�ze

r

The Pharm Exec 50 ranks the world’s largest pharmaceutical companies by global sales of pre-

scription drugs—a key indicator of market change. After last year’s storm of activity, the 50 set a more placid pace, as major players worked on inte-grating blockbuster mergers and licked their wounds after the latest round of Phase III failures. Late-phase problems are nothing new, and drug candidates can come back from them, but there was something particularly heartbreak-ing about the recent crop of dead ends, given the huge unmet medical need as-sociated with these therapies: P� zer’s Dimebon and Lilly’s Semagacestat for Alzheimer’s, Merck’s vicriviroc for HIV, and Roche’s ocrelizumab for rheuma-toid arthritis, to name just a few.

Change was most visible on the macro level. The list of the top 10 com-panies was shaken up a bit, with No-vartis passing Sano� -Aventis to move into second place, and Merck jumping from seventh to fourth. It was also the � rst year the top company crossed the $50 billion mark in sales of prescrip-

tion drugs—as P� zer, fueled by its ac-quisition of Wyeth, grew from $45.4 billion in Rx sales to $58.5 billion. Meanwhile, consolidation in the ranks continues to place a premium on size and scale: This was the � rst year that it took $2 billion in Rx revenues to join the 50. As recently as 10 years ago, you could make the list with revenues of only $500 million.

Overall, the 50 accounted for $593.4 billion in human prescription drug sales in 2010. That represents an increase of nearly 8 percent from 2009, when the total was $550.5 billion. But among the top 10, there was slightly better growth. This year’s group grew its Rx revenues from $319.4 billion in � scal 2009 to $352.5 last year—an in-crease of over 10 percent.

A good percentage of that growth was fueled by mergers and acquisi-tions. In addition to P� zer and its 29 percent increase, big gainers included Merck (58 percent growth after its merger with Schering Plough) and Ab-bott (up nearly 28 percent in the wake of its acquisitions of Solvay and Pira-

mal). But the biggest single-year bump came at a much smaller company: The Irish � rm Warner Chilcott last year ac-quired the pharmaceutical business of Procter & Gamble, including the bil-lion-dollar drug Actonel, and raised its Rx revenues a whopping 111 percent to $2.9 billion.

Looming over the year—and the decade—is the shadow of US health-care reform. Many in pharma feel they have dodged the bullet of new regula-tion and stand to gain as a projected 30 million previously uninsured Amer-icans � nally obtain insurance coverage for healthcare. But the Patient Protec-tion and Affordable Care Act is not the end of the discussion—it’s more like the beginning of an avalanche. The economic forces it sets in motion today will be playing out for payers, patients, providers, and pharma for the foresee-able future, changing the way care is delivered and paid for, creating numer-ous business threats, but, with luck, ending up with the possibility of get-ting a better alignment between help-ing the patient and earning a pro� t.

Revenue Distribution of Top 50

Top 10 accounts for $352.5 billion in sales, which is 59.40% of total revenues of the Top 50

Top 20 accounts for $483.8 billion in sales, which is 81.53% of total revenues of the Top 50

* F

igur

es a

re r

ound

ed



2011 Rank

Company HQ [website]

2010 Rx Sales (USD

billions) [% change from 2009]

2010 R&D spend(USD millions)

2010 Top-Selling Drugs [USD billions]

1 Pfizer New York, New York [pfizer.com]

$58.5 [28.9%] $9,413Lipitor [10.7]Enbrel [3.3]Lyrica [3.1]

2 NovartisBasel, Switzerland [novartis.com]

$42.0 [9.2%] $7,100Diovan/Co-Diovan [6.1]Gleevec/Glivec [4.3]Lucentis [1.5]

3 Sanofi-Aventis Paris, France [sanofi-aventis.com]

$40.3 [–4.1%] $5,147Lantus [4.7]Lovenox [3.7]Taxotere [2.8]

4Merck Whitehouse Station, New Jersey [merck.com]

$39.8 [58.0%] $11,000Singulair [5.0]Remicade [2.7]Januvia [2.4]

5 Roche Basel, Switzerland [roche.com]

$39.1 [4.1%] $8,612Avastin [6.8]MabThera/Rituxan [6.7]Herceptin [5.7]

6 GlaxoSmithKline Brentford, England [gsk.com]

$36.2 [–4.2%] $6,126Seretide/Advair [7.9]Pandemic Flu Vaccine [1.8]Flixotide/Flovent [1.2]

7 AstraZeneca London, England [astrazeneca.com]

$33.3 [1.4%] $4,200Crestor [5.7]Nexium [5.0]Seroquel [4.1]

8 Johnson & Johnson New Brunswick, New Jersey [jnj.com]

$22.4 [–0.4%] $4,432Remicade [4.6]Procrit [1.9]Risperdal [1.5]

9 Eli Lilly Indianapolis, Indiana [lilly.com]

$21.1 [5.4%] $4,880Zyprexa [5.0]Cymbalta [3.5]Alimta [2.2]

10 Abbott Abbott Park, Illinois [abbott.com]

$19.9 [27.7%] $3,724Humira [6.5]Trilipix/TriCor [1.6]Kaletra [1.3]

Sources: corporate data (10K’s, annual reports, etc.) and Pharm Exec estimates N/A = Not Available/Not Applicable * Estimate Figures are rounded

How the listings were compiled: Companies in the Pharm Exec 50 are ranked according to global human prescription drug sales. As far as company documentation allows, generics and vaccines are included; over-the-counter products, royalties, and contract manufacturing revenue are not. In most cases, numbers are taken from annual reports or SEC filings for the fiscal year that ended in 2010. For most American and European companies, that means the year ending Dec. 31, 2010; for many Japanese companies, it means the year ending March 31, 2010. In the case of private companies that do not report results, we have made estimates based on available data, including IMS reports. For companies that report in currencies other than US dollars, we have converted their numbers using the midpoint average interbank rate for the last day of the fiscal year. Some charts that accompany this article are based on numbers from IMS Health. These are based on a different methodology and will not be consistent with the figures we have compiled from financial filings. Percentage growth figures should be treated with caution, because they can be affected by fluctuating exchange rates.



Latin AmericaJapan

Asia/Africa/AustraliaEurope

North America

Latin AmericaJapan

Asia/Africa/AustraliaEurope

North America

42.3%

29.2%

12.4%

10.8%

5.3%

25 Spiriva Handihaler

24 Copaxone

23 Atripla

22 Lovenox

21 Aricept

20 Rituxan

19 Lexapro

18 Humira

17 Zyprexa

16 Neulasta

15 Oxycontin

14 Avastin

13 Cymbalta

12 Enbrel

11 Remicade

10 Epogen

9 Actos

8 Crestor

7 Singulair

6 Seroquel

5 Abilify

4 Advair Diskus

3 Plavix

2 Nexium

1 Lipitor

Sou

rce:

IMS

Hea

lth,

MID

ASS

ourc

e: IM

S H

ealt

h

Global Pharma Sales by Region Market Share Region USD in Billions Growth from 2009

Top 25 US Pharma Products by Sales Product 2010 2009 % Change

334.8 3.2%

230.7 1.8%

98.1 13.3%

85.7 0.4%

42.0 16.3%

7.2 7.6 -5.26 6.3 6.3 FLAT 6.1 5.6 8.92 4.7 4.7 FLAT 4.6 4.0 15.00 4.4 4.2 4.76 4.1 3.7 10.81 3.8 3.0 26.66 3.5 3.4 2.94 3.3 3.2 3.13 3.3 3.2 3.13 3.3 3.3 FLAT 3.2 2.8 14.29 3.1 3.0 3.33 3.1 2.9 6.90 3.0 3.0 FLAT 3.0 2.7 11.11 2.9 2.5 16.00 2.8 2.8 FLAT 2.8 2.6 7.69 2.5 2.3 8.7 2.3 2.8 -17.86 2.2 1.9 15.79 2.2 1.7 29.41 2.0 1.7 17.65

Sales represent audited market for pharma products only (Dec. 2009–Dec 2010)IMS fi gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales

Figures (rounded) in US billions

Worldwide Totals: $791.4 4.2%

TOTAL US SCRIP MARKET: 2010: $307.4 2009: $300.3 2.36%



2011 Rank


2010 Rx Sales (USD


2010 R&D spend(USD Millions)


11 Bristol-Myers Squibb New York [bms.com]

$19.5 [3.6%] $3,566 Plavix [6.7]

12 Teva Petach Tikva, Israel [tevapharm.com]

$16.1 [16.0%] $933 Copaxone [2.9]

13 Amgen Thousand Oaks, California [amgen.com]

$14.7 [1.8%] $2,894 Neulasta/Neupogen [4.8]

14 Bayer Leverkusen, Germany [bayer.com]

$14.5 [–3.6%] $2,320 Betaferon/Betaseron [1.6]

15 Takeda Osaka, Japan [takeda.com]

$14.2 [–0.1%] $3,198 Actos/Glustin [4.2]

16Boehringer Ingelheim Ingelheim, Germany [boehringer-ingelheim.com]

$12.9 [–10.8%] $3,056 Spiriva [3.8]

17 Novo Nordisk Bagsvaerd, Norway [novonordisk.com]

$10.8 [9.9%] $1,709 NovoRapid [2.1]

18 Astellas Tokyo, Japan [astellas.com]

$10.5 [6.0%] $2,109 Prograf [1.9]

19 Daiichi Sankyo Tokyo, Japan [daiichisankyo.com]

$9.8 [20.0%] $2,124 Olmesartan [2.6]

20 Eisai Tokyo, Japan [eisai.com]

$8.4 [8.0%] $1,932 Aricept [3.5]




20 Immunostimulating Agents19 Anti-Alzheimers

18 Hormonal Contraceptives17 Vaccines (Pure, Combo, Other)

16 Antiepileptics15 Multiple Sclerosis

14 Erythropoietins13 Platelet Aggregation Inhibitors

12 ADHD11 Narcotic Analgesics

10 Angiotensin II9 HIV Antivirals

8 Autoimmune Diseases7 Antidepressants

6 Antiulcerants5 Antipsychotics

4 Antidiabetes3 Lipid Regulators

2 Respiratory Agents1 Oncologics

20 Hypnotics & Sedatives19 Vitamins & Minerals

18 Macrolides & Similar Type17 Penicillins

16 Angiotensin II15 Hormonal Contraceptives

14 Antirheumatics13 Calcium Antagonists (Plain & Combo)

12 Thyroid Preps11 Tranquilizers

10 Antiepileptics9 Diuretics

8 Anti-ulcerants7 Respiratory Agents

6 Antidiabetes5 Ace Inhibitors

4 Beta Blockers (Plain & Combo)3 Narcotic Analgesics

2 Antidepressants1 Lipid Regulators

Top 20 Therapeutic Classes by Spending Product 2010 2009 % Change

Top 20 Therapeutic Classes by Prescriptions Class 2010 2009 % Change

22.3 21.5 3.72 19.3 18.1 6.63 18.8 18.6 1.08 16.9 15 12.66 16.1 14.7 9.52 11.9 14.1 -15.60 11.6 11.5 0.87 10.6 9.7 9.28 9.2 8.2 12.19 8.7 8.6 1.16 8.4 8.0 5.00 7.2 6.3 14.28 7.1 6.5 9.23 6.1 6.3 -3.17 5.7 4.9 16.33 5.6 6.9 -18.84 5.0 4.6 8.69 4.8 4.7 2.13 4.5 4.0 12.5 4.2 4.1 2.44

255.4 249.7 2.28 253.6 246.1 3.05 244.3 241.0 1.37 191.5 167.8 14.12 168.7 165.7 1.81 165.0 159.0 3.77 153.3 152.4 0.59 147.1 145.7 0.96 131.0 131.7 -0.53 121.7 115.3 5.55 108.6 104.0 4.42 107.2 105.3 1.8 97.9 94.9 3.16 95.0 92.5 2.70 92.3 93.9 -1.70 83.7 84.4 -0.83 76.1 76.6 -0.65 73.9 69.3 6.64 71.9 69.8 3.01 66.0 65.5 0.76

Figures (rounded) in USD billionsTherapy Class defi ned using ATC-defi ned product groups and synthesized based on proprietary IMS Health defi nitons

Immunostimulating Agents excludes interferons

Rx fi gures (rounded) in millions;Therapy classes defi ned using ATC defi ned product groups and synthesized based on proprietary IMS Health defi nitions

Sou

rce:

IMS

Hea

lth

Sou

rce:

IMS

Hea

lth

TOTAL US SCRIP MARKET: 2010: 3,995.2 2009: 3,949.2 1.16%





2011 Rank


2010 Rx Sales (USD




21 Merck KGaA Darmstadt, Germany [merck.de]

$7.8 [–0.4%] $1,547 Rebif [2.2]

22 Gilead Sciences Foster City, California [gilead.com]

$7.4 [14.2%] $1,073 Atripla [3.0]

23 Baxter International Deerfield, Illinois [baxter.com]

$5.6 [1.3%] $915 Advate [1.7]

24 Mylan Canonsburg, Pennsylvania [mylan.com]

$5.2 [7.5%] $282 EpiPen [0.3]

25 Servier Neuilly-sur-Seine [servier.com]

$4.9 [6.6%] $1,226 Coversil [1.5*]

26 Chugai Tokyo, Japan [chugai-pharm.co.jp]

$4.6 [1.3%] $671 Avastin [0.6]

27 Mitsubishi Tanabe Osaka, Japan [mt-pharma.co.jp]

$4.4 [2.4%] $897 Remicade [0.5]

28 Menarini Florence, Italy [menarini.com]

$4.0* [0.2%] N/A Migard/Allegro [0.1*]

29 Genzyme Cambridge, Massachusetts [genzyme.com]

$4.0 [2.3%] $847 Cerezyme [0.7]

30 Allergan Irvine, California [allergan.com]

$4.0 [7.9%] $805 Botox [1.4]



MAY 2011 www.pharmexec.com 51

25 Galen Holdings24 Purdue

23 Nestle S.A.22 Watson

21 Novo Nordisk20 Eisai

19 Otsuka America18 Gilead17 Mylan16 Forest

15 Takeda14 Boehringer Ingelheim13 Bristol-Myers Squibb

12 Sanofi-Aventis11 Abbott10 Amgen

9 Johnson & Johnson8 GlaxoSmithKline

7 Teva6 Roche

5 Lilly4 Novartis

3 AstraZeneca2 Merck1 Pfizer

25 Aurobindo24 Sanofi-Aventis

23 Par22 Bristol-Myers Squibb

21 Ranbaxy20 Forest

19 West Ward18 Lilly

17 Zydus16 Abbot

15 Dr Reddy14 Actavis U.S.

13 Boehringer Ingelheim12 GlaxoSmithKline

11 Covidien10 AstraZeneca

9 Amneal8 Merck7 Lupin6 Endo

5 Watson4 Pfizer

3 Novartis2 Mylan

1 Teva

25 Singulair24 gabapentin

23 Plavix22 ibuprofen (Rx)

21 oxycodone/acetaminophen20 warfarin sodium19 citalopram HBR

18 metoprolol succinate17 sertraline HCL

16 atenolol15 zolpidem tartrate

14 metoprolol tartrate13 furosemide

12 Lipitor11 alprazolam

10 hydrochlorothiazide9 metformin HCL

8 amoxicillin7 azithromycin

6 omeprazole (RX)5 amlodipine besylate

4 levothyroxine sodium3 lisinopril

2 simvastatin1 hydrocodone/acetaminophen

Top 25 Corporations by U.S. Sales Product 2010 2009 % Change

Top 25 Corporations by Prescriptions Corporation 2010 2009 % Change

Top 25 U.S. Pharma Products by Prescriptions Product 2010 2009 % Change

26.2 27.8 -5.75 18.8 19.8 -5.05 18.3 18.3 FLAT 15.7 13.2 18.94 14.3 13.2 8.33 13.8 14.2 -2.82 13.7 12.1 13.22 13.6 15.0 -9.33 12.9 12.8 0.78 12.7 12.5 1.60 10.8 10.6 1.89 10.4 11.2 -7.14 9.7 9.0 7.77 6.4 7.6 -15.79 6.0 7.9 -24.05 4.7 4.4 6.82 4.7 3.9 20.51 4.7 3.9 20.51 4.6 4.0 15.00 4.6 4.4 4.54 4.5 3.7 21.62 3.3 3.2 3.12 3.2 2.8 14.28 3.2 3.0 6.67 3.0 2.8 7.14

639.3 629.8 1.51 379.9 347.2 9.41 265.3 240.9 10.13 242.0 265.7 -8.92 233.6 235.1 -0.64 141.0 114.5 23.14 134.0 96.2 39.29 104.2 123.3 -15.49 97.9 67.5 45.04 86.8 93.8 -7.46 80.2 91.2 -12.06 72.6 78.2 -7.16 71.1 72.4 -1.79 68.1 71.1 -4.22 63.5 73.5 -13.60 58.1 61.0 -4.75 53.9 34.9 54.44 49.5 49.8 -0.60 45.2 34.3 31.78 44.3 46.2 -4.11 42.5 31.0 37.09 42.2 44.1 -4.31 40.2 48.2 -16.60 40.0 42.1 -4.99 39.7 38.9 2.06

131.2 128.2 2.34 94.1 83.8 12.29 87.4 82.8 5.56 70.5 66.0 6.82 57.2 51.3 11.5 53.4 45.4 17.62 52.6 53.8 -2.23 52.3 52.4 -0.19 48.3 44.3 9.03 47.8 47.9 -0.21 46.3 43.9 5.47 45.3 51.7 -12.38 43.4 43.5 -0.23 38.9 41.1 -5.35 38.0 35.1 8.26 36.3 39.3 -7.63 35.7 34.2 4.38 33.0 26.9 22.68 32.1 27.1 18.45 32.0 31.6 1.27 31.9 30.2 5.63 31.1 30.3 2.64 29.5 29.9 -1.34 29.3 25.4 15.35 28.7 28.6 0.35

Figures (rounded) in millions

Sou

rce:

IMS

Hea

lth

Sou

rce:

IMS

Hea

lth

Sou

rce:

IMS

Hea

lth




Figures (rounded) in billions

Figures (rounded) in millions



2011 Rank


2010 Rx Sales (USD




31 Forest New York, New York [frx.com]

$3.9 [7.4%] $1,054 Lexapro [2.3]

32 CSL Victoria, Australia [csl.com.au]

$3.8 [–3.6%] $272 N/A [N/A]

33 UCB Brussels, Belgium [ucb.com]

$3.7 [–4.0%] $1,044 Keppra [1.2]

34 Otsuka Tokyo, Japan [www.otsuka.co.jp/en/]

$3.6* [–46.1%] N/A Abilify [4.5*]

35 Celgene Summit, New Jersey [celgene.com]

$3.5 [36.7%] $1,128 Revlimid [2.5]

36 Biogen Idec Weston, Massachusetts [biogenidec.com]

$3.5 [10.1%] $1,249 Avonex [3.5]

37 Shire Dublin, Ireland [shire.com]

$3.1 [16.1%] $662 Vyvanse [0.6]

38 Alcon Hünenberg, Switzerland [alcon.com]

$3.1 [14.5%] $747 Glaucoma products [1.3]

39 Warner Chilcott Dublin, Ireland [wcrx.com]

$2.9 [111.0%] $147 Actonel [1.0]

40 Cephalon Frazer, Pennsylvania [cephalon.com]

$2.8 [28.3%] $440 Provigil [1.1]




20 Calcium Antagonists19 Hormonal Contraception

18 Antirheumatics (Non-steroid)17 Multiple Sclerosis

16 Vaccines15 Erythropoietin Products

14 Cephalosporins & Combs13 Narcotic Analgesics

12 Antiepileptics11 Platelet Aggreg. Inhibitors

10 HIV Antivirals9 Antidepressants

8 Autoimmune Agents7 Antipsychotics

6 Angiotensin II Antagonists5 Antiulcerants4 Antidiabetics

3 Respiratory Agents2 Lipid Regulators

1 Oncologics

20 Diovan (valsartan)19 Herceptin (trastuzumab)

18 Lovenox (enoxaparin sodium)17 Actos (pioglitazone)16 Aricept (donepezil)

15 Lantus (insulin glargine)14 Mabthera (rituximab)

13 Abilify (aripiprazole)12 Singulair (montelukast)11 Avastin (bevacizumab)

10 Zyprexa (olanzapine)9 Humira (adalimumab)8 Remicade (infliximab)

7 Enbrel (etanercept)6 Crestor (rosuvastatin)5 Seroquel (quetiapine)

4 Nexium (esomeprazole)3 Seretide (fluticasone/salmeterol)

2 Plavix (clopidogrel)1 Lipitor (atorvastatin)

Sou

rce:

IMS

Hea

lth,

MID

ASS

ourc

e: IM

S H

ealt

h, M

IDAS

Sou

rce:

IMS

Hea

lth

Top 20 Global Therapy Classes by Sales Product 2010 % Change

Top US Patent ExpiriesRank Product/Company LOE date 2010 Sales Total Rx 2010

Top 20 Leading Global Products by Sales Product 2010 % Change

1 LIPITOR/Pfi zer Q4 2011 7,244.1 45.82 ADVAIR DISKUS/GSK Q3 2011 4,711.4 19.73 ZYPREXA/Eli Lilly Q4 2011 2,957.6 5.34 LEVAQUIN/Ortho-McNeil Q2 2011 1,522.4 10.95 XALATAN/Pfi zer Q1 2011 710.8 6.96 FEMARA/Novartis Q2 2011 681.6 1.37 ZYPREXA ZYDIS/Eli Lilly Q4 2011 331.1 0.48 ADVAIR HFA/GSK Q3 2011 254.6 1.19 PATANOL/Alcon Q2 2011 241.1 2.310 PATADAY/Alcon Q2 2011 215.0 2.111 VIVELLE-DOT/Novogyne Q1 2011 215.0 3.2

56.0 6.7 36.4 2.0 35.8 7.0 34.4 12.2 27.2 -6.7 26.6 4.5 25.4 9.0 20.7 14.7 20.2 3.4 15.4 13.2 14.6 1.5 12.6 -3.3 12.0 6.4 11.6 5.8 10.6 -1.8 10.5 3.5 9.8 13.9 9.8 3.6 9.5 5.3 9.2 -8.8

12,656.1 -6.2 8,816.5 -3.4 8,468.6 4.4 8,361.5 1.3 6,815.6 13.2 6,796.3 24 6,167.2 5.2 6,038.6 10.3 5,959.5 19.7 5,736.3 6.6 5,532.2 11.1 5,465.4 9.1 5,430.3 16.3 5,033.2 7.8 4,685.3 16.7 4,432.1 8.5 4,317.3 3.9 4,282.0 -5.3 4,165.1 6.7 4,156.4 3.5

Sales fi gures (rounded) in USD millions; Rx fi gures rounded LOE = Loss of Exclusivity

Figures (rounded) in USD billions (Dec 2009–Dec 2010)Sales represent audited market for pharma products only

IMS fi gures do not account for off-invoice discounts/rebates and can vary from reported mfr sales

Figures (rounded) in USD millions (Dec. 2009–Dec. 2010) Sales represent audited market for pharma products only Figures do not account for off-invoice discounts/rebates and can vary from reported mfr sales


TOTAL US SCRIP MARKET: 2010: $123,315.5 2009: 116,221.7 6.10% Increase



2011 Rank


2010 Rx Sales (USD




41 Watson Corona, California [watson.com]

$2.6 [27.0%] $296 CNS generics [0.9]

42 Lundbeck Copenhagen, Denmark [lundbeck.com]

$2.6 [–0.6%] $542 Cipralex/Lexapro [1.5]

43 Kyowa Hakko Kirin Tokyo, Japan [kyowa-kirin.co.jp]

$2.6 [14.7%] $429 Nesp/Espo [0.6*]

44 Dainippon Sumitomo Osaka, Japan [ds-pharma.co.jp]

$2.6 [20.1%] $554 Amlodin [0.6]

45 Shionogi Osaka, Japan [shionogi.co.jp]

$2.4* [35.2%] $135 Crestor [0.3]

46 Actavis Hafnarfjörður, Iceland [actavis.com]

$2.4* [32.5%] N/A Oxycodone [0.4]

47 Hospira Lake Forest, Illinois [hospira.com]

$2.3 [13.3%] $301 N/A [N/A]

48 Nycomed Zurich, Switzerland [nycomed.com]

$2.2 [–20.2%] $281 Pantoprazole [1.2]

49 Apotex North York, Ontario, Canada [apotex.com]

$2.1* [–19.2%] N/A N/A [N/A]

50 Stada Bad Vilbel, Germany [stada.de]

$2.1 [–5.0%] $73 Generic omeprazole [0.1]


TOTALS: 2010: $593.4 billion 2009: $550.5 billion 7.79%



1. Pfizer President and CEO Jeff Kindler retired, succeeded by Ian C. Read. George Lorch elected Non-Execu-tive Chairman of the Board. Sutent ap-proved in EU for treatment of pancreatic neuro-endocrine tumors. Launched Prevnar 13, a vaccine against 13 strains of pneumococcal diseases in infants and young children. Also has 118 products in the R&D pipeline and had 1,300 clinical trials in 2010.

2. Novartis Completed purchase of Alcon from Nestlé for $38.7 billion. Jonathan Symonds promoted to CFO. David Epstein replaced CEO Joe Jimenez as Division Head, Pharmaceuticals. Thirteen major pharmaceutical approvals in the US, Europe, and Japan, with 147 products in development. Tasigna was ap-proved in the US, the EU, Japan, and Swit-zerland for patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a form of blood cancer. Menveo (vaccine against meningococcal disease) launched in the US, EU, and parts of Latin America and Asia. Sandoz launched generic enoxaparin, its most successful launch to date, and acquired Oriel Therapeutics.

3. Sanofi-Aventis Initiated acquisition of Genzyme for $16.6 billion (completed in April) and finished acquisition of OTC company Chattem. Began collaboration programs with Harvard and Columbia Universities and a research alliance with Scripps Genomic Medicine. Jevtana approved in US for second-line treatment of metastatic hormone-refractory prostate cancer.

4. Merck Elected Kenneth Frazier CEO. Bought Inspire for $430 million. Rotateq vaccine awarded top honor at Prix Galien USA 2010. Merck BioVentures entered into an alliance with Parexel for biosimilar devel-opment. Signed commercialization agree-ment with Lundbeck for Sycrest and a letter of mutual intent with China’s Sinopharm. Pipeline has more than 20 late-stage can-didates. Licensed oral mTOR inhibitor for multiple cancers from Ariad. Oral hepatitis C protease inhibitor Boceprevir granted Priority Review status by FDA.

5. Roche Rituxan approved in US as first-line treatment for chronic lymphocytic leukemia (CLL) and relapsed/refractory CLL. Tarceva approved in US and EU for first-line treatment of non-small-cell lung cancer after chemotherapy. FDA rejected use of Avastin as a treatment for metastatic breast cancer; Roche has requested a hearing to appeal this decision. Daniel O’Day appointed COO of the Pharmaceuticals division. Alan Hippe named CFO. Jean-Jacques Garaud appointed Head of Roche Pharma Research and Early Development.

6. GlaxoSmithKline Benlysta (belimumab, the first new lupus treatment in 60 years) approved by FDA in March. Six products in total approved by US and EU; seven more filed with regulators. Malaria vaccine in Phase III trials in Africa, with 30 other late-stage assets. Julian Heslop retired as CFO, succeeded by Simon Dingemans. Patents for active ingredients in Seretide/Advair expired.

7. AstraZeneca Crestor substance patent upheld in US court. Approvals include Vimovo (naproxen/esomeprazole magnesium) in US and EU and Brilique (atherothrombotic event prevention) in

EU. Kombiglyze XR, the only once-daily dose of DPP4/metformin, developed with Bristol-Myers Squibb, also approved in US. Nine molecules in Phase III trials or submitted for regulatory approval, with another 92 projects in development. Com-pleted deal with Rigel for development of fostamatinib (rheumatoid arthritis).

8. Johnson & Johnson Completed tender offer for Crucell N.V. in February 2011; acquired 98.93 percent of shares. Products under regulatory review include: Rivaroxoban for stroke prevention in pa-tients with atrial fibrillation (US), Telaprevir for hepatitis C (US and EU), Abiraterone acetate for metastatic advanced prostate (US and EU), and rilpivirine for HIV. Eight more candidates planned for regulatory submission from 2011 to 2013.

9. Eli Lilly Completed acquisition of Alnara and Avid Radiopharmaceuticals. Launched statin Livalo in the US with part-ner Kowa. Has 68 molecules in develop-ment. Several monoclonal antibodies for cancer in late-stage development. Phase III candidates include Necitumumab for non-small-cell lung cancer and Ramu-cirumab for metastatic breast and gastric cancers. Signed commercialization deal with Acrux for newly approved experimen-tal testosterone solution Axiron.

10. Abbott The year was marked by acquisitions, including the pharmaceuti-cal business of Solvay for $6.1 billion plus milestones, and Piramal Healthcare’s Healthcare Solutions business, a leader in the Indian branded generics market, for $2.2 billion in cash, plus $1.6 billion in annual payments through 2014. Additional acquisitions included Advanced Medical Op-tics, STARLIMS Technologies (informatics), and the remaining shares of Facet Biotech.

The Top 10 Year In Review

Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Life Sciences Practice. He can be reached at [email protected]

Patrick Clinton is Marketing Director in the Health & Life Sciences practice of Oliver Wyman. He can be reached at [email protected]

About the Authors

pharmaceutical executive top 50 pharma companies report

Documents